About: Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors
Creator	Mikkelsen, Christina Erikstrup, Christian Gybel-Brask, Mikkel Hjalgrim, Henrik Mikkelsen, Susan Mølbak, Kåre Patrick, ; Robert, ; Sørensen, Erik Ullum, Henrik Anna, ; Birger, Ole Bitten, ; Bjarne, ; Boldsen, Jens Brooks, Terrence Christoffer, ; Dinh, Manh Dorte, ; Harritshøj, ; Haunstrup, Thure Holm, Kinggaard Hother, Egeberg Jensen, Aagaard Khoa, ; Lillevang, Thue Møller, Kuno Nilsson, Christine Pedersen, Vestager Saekmose, Susanne Skov, Leo Søren, ;
Source	MedRxiv
abstract	Background: The pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has tremendous consequences for our societies. Knowledge of the seroprevalence of SARS-CoV-2 is needed to accurately monitor the spread of the epidemic and also to calculate the infection fatality rate (IFR). These measures may help the authorities to make informed decisions and adjust the current societal interventions. Blood donors comprise approximately 4.7% of the similarly aged population of Denmark and blood is donated in all areas of the country. The objective of this study was to perform real-time seroprevalence surveying among blood donors as a tool to estimate previous SARS-CoV-2 infections and the population based IFR. Methods: All Danish blood donors aged 17-69 years giving blood April 6 to 17 were tested for SARS-CoV-2 immunoglobulin M and G antibodies using a commercial lateral flow test. Antibody status was compared between areas and an estimate of the IFR was calculated. The seroprevalence was adjusted for assay sensitivity and specificity taking the uncertainties of the test validation into account when reporting the 95% confidence intervals (CI). Results: The first 9,496 blood donors were tested and a combined adjusted seroprevalence of 1.7% (CI: 0.9-2.3) was calculated. The seroprevalence differed across areas. Using available data on fatalities and population numbers a combined IFR in patients younger than 70 is estimated at 82 per 100,000 (CI: 59-154) infections. Conclusions: The IFR was estimated to be slightly lower than previously reported from other countries not using seroprevalence data. The IFR, including only individuals with no comorbidity, is likely several fold lower than the current estimate. This may have implications for risk mitigation. We have initiated real-time nationwide anti-SARS-CoV-2 seroprevalence surveying of blood donations as a tool in monitoring the epidemic.
has issue date	2020-04-28(xsd:dateTime)
bibo:doi	10.1101/2020.04.24.20075291
has license	medrxiv
sha1sum (hex)	c6ffc647a841257cc40d125408caca01651ee7ba
schema:url	https://doi.org/10.1101/2020.04.24.20075291
resource representing a document's title	Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors
resource representing a document's body	covid:c6ffc647a841257cc40d125408caca01651ee7ba#body_text
is schema:about of	named entity 'DECISIONS' named entity 'MAKE' named entity 'COMPRISE' named entity 'SURVEYING' named entity 'areas' named entity 'measures' named entity 'These' named entity 'tool' named entity 'objective' named entity 'Denmark' named entity 'study' named entity 'blood' named entity 'IFR' named entity 'SARS-CoV-2' named entity 'IFR' named entity 'infection fatality rate' named entity 'blood donors' named entity 'infection fatality rate' named entity 'antibody' named entity 'population immunity' named entity 'blood donor' named entity 'medRxiv' named entity 'preprint' named entity 'preprint' named entity 'COVID' named entity 'IFR' named entity 'current literature' named entity 'preprint' named entity 'seroprevalence' named entity 'seropositivity' named entity 'population immunity' named entity 'blood donors' named entity 'respiratory assistance' named entity 'SARS-CoV-2' named entity 'curfew' named entity 'social distancing' named entity 'seroprevalence' named entity 'screening tests' named entity 'preprint' named entity 'Gold Standard' named entity 'background population' named entity 'IgG' named entity 'blood donations' named entity 'preprint' named entity 'SARS-CoV-2' named entity 'IFR' named entity 'preprint' named entity 'SARS-CoV-2' named entity 'IFR' named entity 'antibodies' named entity 'SARS-CoV-2' named entity 'IFR' named entity 'preprint' named entity 'antibody'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software